Amanda J. Redig

6.4k total citations · 3 hit papers
39 papers, 3.1k citations indexed

About

Amanda J. Redig is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amanda J. Redig has authored 39 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 19 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amanda J. Redig's work include Lung Cancer Treatments and Mutations (11 papers), Retinoids in leukemia and cellular processes (5 papers) and Lung Cancer Research Studies (5 papers). Amanda J. Redig is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Retinoids in leukemia and cellular processes (5 papers) and Lung Cancer Research Studies (5 papers). Amanda J. Redig collaborates with scholars based in United States, Japan and Canada. Amanda J. Redig's co-authors include Hidayatullah G. Munshi, Leonidas C. Platanias, Paul J. Catalano, Ayal A. Aizer, Brian M. Alexander, Daniel Cagney, Allison Martin, Pasi A. Jänne, Suzanne E. Dahlberg and Geoffrey R. Oxnard and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Amanda J. Redig

39 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast cancer as a systemic disease: a view of metastasis

2013 545 citations Amanda J. Redig et al. profile →
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

2018 513 citations Geoffrey R. Oxnard, Daniel B. Costa et al. profile →
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

2017 500 citations Daniel Cagney, Allison Martin et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda J. Redig United States	22	1.5k	1.5k	1.2k	648	386	39	3.1k
Mark N. Kirstein United States	21	1.4k 0.9×	1.0k 0.7×	1.4k 1.2×	365 0.6×	473 1.2×	56	3.4k
Timothy R. Wilson United States	32	2.2k 1.4×	1.1k 0.8×	2.3k 2.0×	961 1.5×	373 1.0×	88	4.3k
Rafael Santana-Dávila United States	22	1.7k 1.1×	1.2k 0.8×	1.7k 1.4×	671 1.0×	243 0.6×	70	3.7k
Stephen Francis United States	23	1.3k 0.9×	478 0.3×	834 0.7×	1.0k 1.6×	493 1.3×	73	3.3k
Toru Kumagai Japan	32	1.4k 0.9×	1.4k 1.0×	1.1k 0.9×	741 1.1×	77 0.2×	156	3.1k
Richard Sesboüé France	27	1.2k 0.8×	806 0.6×	1.0k 0.9×	570 0.9×	137 0.4×	91	2.7k
Takashi Kijima Japan	26	1.4k 0.9×	1.2k 0.8×	1.3k 1.1×	320 0.5×	91 0.2×	167	3.4k
Leonard J. Appleman United States	29	1.5k 1.0×	1.2k 0.8×	1.3k 1.1×	563 0.9×	128 0.3×	178	3.3k
John J. Bissler United States	38	1.2k 0.8×	1.7k 1.1×	2.1k 1.8×	169 0.3×	358 0.9×	149	5.6k
Angelo Rosolen Italy	31	681 0.4×	745 0.5×	907 0.8×	315 0.5×	179 0.5×	82	2.5k

Countries citing papers authored by Amanda J. Redig

Since Specialization

Citations

This map shows the geographic impact of Amanda J. Redig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda J. Redig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda J. Redig more than expected).

Fields of papers citing papers by Amanda J. Redig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda J. Redig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda J. Redig. The network helps show where Amanda J. Redig may publish in the future.

Co-authorship network of co-authors of Amanda J. Redig

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda J. Redig. A scholar is included among the top collaborators of Amanda J. Redig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda J. Redig. Amanda J. Redig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanborn, Rachel E., Minal Patel, Jordi Rodón, et al.. (2024). 991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors. Annals of Oncology. 35. S675–S676. 1 indexed citations

Hung, Yin P., Amanda J. Redig, Jason L. Hornick, & Lynette M. Sholl. (2020). ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis. Modern Pathology. 33(11). 2256–2268. 26 indexed citations

Guerra, Stephanie, Ophélia Maertens, Ryan Kuzmickas, et al.. (2020). A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell. 37(5). 705–719.e6. 35 indexed citations

Cagney, Daniel, Allison Martin, Paul J. Catalano, et al.. (2018). Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology. 126(3). 511–518. 17 indexed citations

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

Cagney, Daniel, Allison Martin, Paul J. Catalano, et al.. (2017). Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology. 19(11). 1511–1521. 500 indexed citations breakdown →

Redig, Amanda J., Marzia Capelletti, Suzanne E. Dahlberg, et al.. (2016). Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer. Clinical Cancer Research. 22(13). 3148–3156. 53 indexed citations

Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations

Altman, Jessica K., Antonella Sassano, Surinder Kaur, et al.. (2011). Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors. Clinical Cancer Research. 17(13). 4378–4388. 85 indexed citations

10.

Redig, Amanda J., Eliza Vakana, & Leonidas C. Platanias. (2011). Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL. Leukemia & lymphoma. 52(sup1). 45–53. 26 indexed citations

11.

Redig, Amanda J., Robert E. Brannigan, Steven J. Stryker, Teresa K. Woodruff, & Jacqueline S. Jeruss. (2010). Incorporating fertility preservation into the care of young oncology patients. Cancer. 117(1). 1–10. 50 indexed citations

12.

Dangi‐Garimella, Surabhi, et al.. (2010). Rho-ROCK-Myosin Signaling Meditates Membrane Type 1 Matrix Metalloproteinase-induced Cellular Aggregation of Keratinocytes. Journal of Biological Chemistry. 285(36). 28363–28372. 14 indexed citations

13.

Redig, Amanda J. & Hidayatullah G. Munshi. (2009). Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy. The American Journal of Medicine. 123(1). 87.e1–87.e6. 88 indexed citations

14.

Joshi, Sonali, Surinder Kaur, Amanda J. Redig, et al.. (2009). Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proceedings of the National Academy of Sciences. 106(29). 12097–12102. 63 indexed citations

15.

Redig, Amanda J., Antonella Sassano, Beata Majchrzak-Kita, et al.. (2009). Activation of Protein Kinase Cη by Type I Interferons. Journal of Biological Chemistry. 284(16). 10301–10314. 18 indexed citations

16.

Redig, Amanda J. & Leonidas C. Platanias. (2008). Protein kinase C signalling in leukemia. Leukemia & lymphoma. 49(7). 1255–1262. 13 indexed citations

17.

Katsoulidis, Efstratios, Nathalie Carayol, Jessica K. Altman, et al.. (2008). Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2. Journal of Biological Chemistry. 283(18). 12034–12042. 31 indexed citations

18.

Redig, Amanda J. & Leonidas C. Platanias. (2007). The Protein Kinase C (PKC) Family of Proteins in Cytokine Signaling in Hematopoiesis. Journal of Interferon & Cytokine Research. 27(8). 623–636. 44 indexed citations

19.

Altman, Jessica K., Efstratios Katsoulidis, Barbara Kroczyńska, et al.. (2007). Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses. Journal of Biological Chemistry. 283(4). 1992–2001. 37 indexed citations

20.

Redig, Amanda J. & David G. Besselsen. (2001). Detection of rodent parvoviruses by use of fluorogenic nuclease polymerase chain reaction assays.. PubMed. 51(4). 326–31. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact